ESLA Q3 2022 Earnings — Estrella Immunopharma, Inc. Revenue & Financial Results | Market Cap Arena

ESLAEstrella Immunopharma, Inc.

$53M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$549,180

Net Income

-$344,863

EPS (Diluted)

$-0.06

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$513,128

Free Cash Flow

-$513,128

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$46M

Total Liabilities

$2M

Stockholders' Equity

$43M

Cash & Equivalents

$73,752

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$549,180	-$108,110	-408.0%
Net Income	-$344,863	-$107,547	-220.7%